Maybe more than merely a sensible choice, DrMonoply ?I believe...

Maybe more than merely a sensible choice, DrMonoply ?

I believe that Professor Rohan has all the qualification to be rated as a perfect choice as ACW's Chief Medical Officer.
From ACW's Release:
The fact that the Market today has ACW in the GREEN on a FRIDAY when most other stocks are in the RED at present it appears that many others may be thinking the same.

Professor Rolan is a clinical pharmacologist and drug development consultant and one of Australia's most
experienced clinical trial investigators and drug developers, having taken drugs from first human administration
to market. His career has spanned academic medicine (Professor of Clinical Pharmacology and Director of
Innovation at The University of Adelaide) and pharmaceutical medicine. He has extensive expertise in the
development of medicines as principal investigator in more than 750 early phase proof-of-concept, clinical
pharmacology, drug interaction and special patient groups studies.
Professor Rolan’s prior industry roles have included Medical Director of the U.K.'s largest phase 1 contract
research organisation, Medeval, Chief Medical Officer for ASX listed biotech company, Bionomics Limited and
Director of Drug Development for Singapore's first listed pharmaceutical company, iX Biopharma. Professor
Rolan continues to advise on drug development for the international pharmaceutical industry, with a focus on
the development of biomarkers, evaluation of novel therapies and mechanisms of disease, as well as conduct
clinical practice in chronic pain management and headache.
Professor Rolan holds numerous academic and professional qualifications including a Bachelor of Medicine
and Bachelor of Surgery (MBBS), and a Doctor of Medicine (MD). He also holds fellowships of the Royal
Australian College of Physicians (FRACP), the Faculty of Pharmaceutical Medicine, Royal College of
Physicians, (FFPM) and the Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists,
(FFPMANZCA).

Dr Steven Gourlay, Actinogen CEO and MD, commented:
“We are delighted to have Professor Paul Rolan join the Actinogen leadership team as Chief Medical Officer.
Paul brings invaluable specialist skills to the CMO role that complement the current team and we look forward
to his contribution to the advancement of our expanded Xanamem® clinical development pipeline. The
Xanamem pipeline now includes a Phase 2 trial in Depression as well as trials investigating the treatment of
people with early stage Alzheimer’s Disease and Fragile X Syndrome.
“I look forward to working closely with Paul to help make a material difference to the quality of life for people
and their families living with these serious neurological conditions.”